Protagonist Therapeutics, Inc.
PRTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Apr 1, 2026
4dMarket Overview
Stock performance and key metrics
PRTX News
Catalyst Timeline
1 upcoming, 0 past
Phase 3Next
Open-label rusfertide Phase 3 Results Expected
Apr 1, 2026EstimatedOpen-label rusfertide46
Primary completion for Open-label rusfertide trial (NCT06033586) in Polycythemia Vera
SourceDrug Pipeline
Open-label rusfertide
Polycythemia Vera
Rusfertide
Polycythemia Vera
PTG-300
Hereditary Hemochromatosis
PN-943
Ulcerative Colitis Chronic Moderate
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-label rusfertide | Phase 3 | Polycythemia Vera | - | - |
Rusfertide | Phase 3 | Polycythemia Vera | - | - |
PTG-300 | Phase 2 | Hereditary Hemochromatosis | - | - |
PN-943 | Phase 2 | Ulcerative Colitis Chronic Moderate | - | - |
Polycythemia Vera
2 drugs in this indication
Ulcerative Colitis Chronic Moderate
1 drug in this indication
Hereditary Hemochromatosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply